57th ASH Annual Meeting and Exposition (December 5-8, 2015): 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Targets and Therapeutic Approaches

Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy Oral and Poster Abstracts
Oral

W304ABCD, Level 3 (Orange County Convention Center)

Moderators:

Attaya Suvannasankha, Indiana University School of Medicine and Mala Shanmugam, PhD, Emory University

Disclosures:

No relevant conflicts of interest to declare.

6:15 PM

Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs

Rakesh Verma, PhD¹, Zifeng Mai, MS¹^*, Mina Xu, M.D.²^*, Lin Zhang¹^*, Kavita Dhodapkar, MBBS³^* and Madhav V Dhodapkar, MD¹

¹Yale Cancer Center, New Haven, CT
²Department of Pathology, Yale University School of Medicine, New Haven, CT
³Yale University, New Haven, CT

6:30 PM

914

Bone Marrow Niche - Multiple Myeloma Cross-Talk Generates Bortezomib Resistance

Salvador Alonso, M.D.^*, William Matsui, MD, Richard J Jones, MD and Gabriel Ghiaur, MD, PhD

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

6:45 PM

915

A New Model for Studying the Dissemination of Myeloma Cells throughout the Bone Marrow Using Embryonic Zebrafish

Aldo M Roccaro, MD, PhD¹, Antonio Sacco, BS¹^*, Dongdong Ma, M.D. Ph.D.²^*, Jiantao Shi³^*, Yuji Mishima, PhD¹^*, Michele Moschetta, MD⁴^*, Robert I. Handin, M.D² and Irene M. Ghobrial, MD⁵

¹Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
³Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

7:00 PM

916

Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma

Nicola Amodio, PhD¹^*, Enrica Romeo¹^*, Maria Angelica Stamato¹^*, Eugenio Morelli, MD¹^*, Mariateresa Fulciniti, PhD²^*, Lavinia Raimondi³^*, Marzia Leotta¹^*, Maria Teresa Di Martino¹^*, Pierosandro Tagliaferri, MD⁴^*, Nikhil C. Munshi, MD⁵ and Pierfrancesco Tassone, MD⁴^*

¹Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
²Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
³Laboratory of Tissue Engineering-Innovative Technology Platforms for Tissue Engineering, Rizzoli Orthopedic Institute, Palermo, Italy
⁴Salvatore Venuta Campus, Magna Graecia University, Catanzaro, Italy
⁵The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

7:15 PM

917

Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma

Xiaohui Zhang, M.D., Ph.D.^1,2^*, Jing Lu, Ph.D.³^*, Yimin Qian, Ph.D.³^* and Robert Z. Orlowski, Ph.D., M.D.^4,5

¹Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Hematology, Second Affiliated Hospital of Soochow University, Suzhou City, China
³Arvinas, LLC, New Haven, CT
⁴Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

7:30 PM

918

The Hypoxia-Selective Epigenetic Agent, Rrx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells

Deepika Sharma Das, PhD¹^*, Arghya Ray, PhD¹, Yan Song, Ph.D¹^*, Paul Richardson, MD¹, Bryan Oronsky²^*, Jan Scicinski²^*, Dharminder Chauhan, PhD¹ and Kenneth C Anderson, MD³

¹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²EpicentRx, CA, CA
³LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

See more of: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.O2.6 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Targets and Therapeutic Approaches